Stefano Bibbò, Gustav Ahlström, Giovanni Mario Pes, David Y. Graham, Lars Engstrand, Elettra Merola, Maria Pina Dore
{"title":"在幽门螺杆菌感染的成人中，有或没有大剂量罗伊氏乳杆菌的短质子泵抑制剂治疗对肠道微生物群的恢复力","authors":"Stefano Bibbò, Gustav Ahlström, Giovanni Mario Pes, David Y. Graham, Lars Engstrand, Elettra Merola, Maria Pina Dore","doi":"10.1111/hel.70064","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p><i>Helicobacter pylori</i> eradication therapy typically consists of a combination of antibiotics and an antisecretory drug. Probiotics may be added to reduce side effects and possibly improve outcomes.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>We conducted a double-blind, randomized trial of pantoprazole plus either <i>Lactobacillus reuteri</i> (Gastrus) (high dose) or a matching placebo to assess the impact on the gut microbiota of <i>H. pylori</i>-positive adults. Fecal samples were collected at baseline and after one and 2 months for shotgun metagenomic sequencing.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 26 patients were recruited and completed therapy. <i>L. reuteri</i> was only detected in the group that received supplemental <i>L. reuteri</i> and only at the 1-month post-treatment interval. <i>L. reuteri</i> failed to colonize for long-term the gut, and challenge with <i>L. reuteri</i> failed to alter alpha-diversity (Shannon index) or beta-diversity (community ordination) metrics at any time point. Machine learning (PLS-DA) analysis identified the presence of <i>L. reuteri</i> as the most distinguishing feature at 1 month. No other taxa showed a significant difference between groups.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Short-term administration of pantoprazole and <i>L. reuteri</i> had no lasting effects on gut microbial composition. While <i>L. reuteri</i> transiently bloomed during supplementation, the overall gut microbiota showed resilience, returning to baseline shortly after therapy.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>Identifier: NCT03404440</p>\n </section>\n </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.70064","citationCount":"0","resultStr":"{\"title\":\"Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High-Dosage L. reuteri in H. pylori-Infected Adults\",\"authors\":\"Stefano Bibbò, Gustav Ahlström, Giovanni Mario Pes, David Y. Graham, Lars Engstrand, Elettra Merola, Maria Pina Dore\",\"doi\":\"10.1111/hel.70064\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p><i>Helicobacter pylori</i> eradication therapy typically consists of a combination of antibiotics and an antisecretory drug. Probiotics may be added to reduce side effects and possibly improve outcomes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Materials and Methods</h3>\\n \\n <p>We conducted a double-blind, randomized trial of pantoprazole plus either <i>Lactobacillus reuteri</i> (Gastrus) (high dose) or a matching placebo to assess the impact on the gut microbiota of <i>H. pylori</i>-positive adults. Fecal samples were collected at baseline and after one and 2 months for shotgun metagenomic sequencing.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 26 patients were recruited and completed therapy. <i>L. reuteri</i> was only detected in the group that received supplemental <i>L. reuteri</i> and only at the 1-month post-treatment interval. <i>L. reuteri</i> failed to colonize for long-term the gut, and challenge with <i>L. reuteri</i> failed to alter alpha-diversity (Shannon index) or beta-diversity (community ordination) metrics at any time point. Machine learning (PLS-DA) analysis identified the presence of <i>L. reuteri</i> as the most distinguishing feature at 1 month. No other taxa showed a significant difference between groups.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Short-term administration of pantoprazole and <i>L. reuteri</i> had no lasting effects on gut microbial composition. While <i>L. reuteri</i> transiently bloomed during supplementation, the overall gut microbiota showed resilience, returning to baseline shortly after therapy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>Identifier: NCT03404440</p>\\n </section>\\n </div>\",\"PeriodicalId\":13223,\"journal\":{\"name\":\"Helicobacter\",\"volume\":\"30 5\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.70064\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Helicobacter\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/hel.70064\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Helicobacter","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hel.70064","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High-Dosage L. reuteri in H. pylori-Infected Adults
Background
Helicobacter pylori eradication therapy typically consists of a combination of antibiotics and an antisecretory drug. Probiotics may be added to reduce side effects and possibly improve outcomes.
Materials and Methods
We conducted a double-blind, randomized trial of pantoprazole plus either Lactobacillus reuteri (Gastrus) (high dose) or a matching placebo to assess the impact on the gut microbiota of H. pylori-positive adults. Fecal samples were collected at baseline and after one and 2 months for shotgun metagenomic sequencing.
Results
A total of 26 patients were recruited and completed therapy. L. reuteri was only detected in the group that received supplemental L. reuteri and only at the 1-month post-treatment interval. L. reuteri failed to colonize for long-term the gut, and challenge with L. reuteri failed to alter alpha-diversity (Shannon index) or beta-diversity (community ordination) metrics at any time point. Machine learning (PLS-DA) analysis identified the presence of L. reuteri as the most distinguishing feature at 1 month. No other taxa showed a significant difference between groups.
Conclusion
Short-term administration of pantoprazole and L. reuteri had no lasting effects on gut microbial composition. While L. reuteri transiently bloomed during supplementation, the overall gut microbiota showed resilience, returning to baseline shortly after therapy.
期刊介绍：
Helicobacter is edited by Professor David Y Graham. The editorial and peer review process is an independent process. Whenever there is a conflict of interest, the editor and editorial board will declare their interests and affiliations. Helicobacter recognises the critical role that has been established for Helicobacter pylori in peptic ulcer, gastric adenocarcinoma, and primary gastric lymphoma. As new helicobacter species are now regularly being discovered, Helicobacter covers the entire range of helicobacter research, increasing communication among the fields of gastroenterology; microbiology; vaccine development; laboratory animal science.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
